Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Kiely (Sheffied, United Kingdom), A. Swift (Sheffield, United Kingdom), M. Cogliano (Sheffield, United Kingdom), L. Kendall (Stevenage, United Kingdom), C. Oram (Sheffield, United Kingdom), D. Capener (Sheffield, United Kingdom), A. Rothman (Sheffield, United Kingdom), P. Garg (Sheffield, United Kingdom), C. Johns (Sheffield, United Kingdom), M. Austin (Sheffield, United Kingdom), J. Pickworth (Sheffield, United Kingdom), P. Hickey (Sheffield, United Kingdom), T. Kahn (Stevenage, United Kingdom), A. Lawrie (Sheffield, United Kingdom), R. Condliffe (Sheffield, United Kingdom), F. Wilson (Stevenage, United Kingdom), J. Wild (Sheffield, United Kingdom). A prospective study comparing the repeatability and sensitivity to change of non-invasive endpoints in pulmonary arterial hypertension: the RESPIRE study. 496

Member's Comments

No comment yet.

Related content which might interest you: End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Source: Eur Respir J 2009; 34: 231-242 Year: 2009 Non-invasive estimation of pulmonary artery pressure and resistance with CMR imaging: Derivation and prospective validation cohort study Source: Annual Congress 2012 - Functional imaging of the lung parenchyma, tumours and circulation Year: 2012 Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study Source: Eur Respir J, 50 (1) 1700217; 10.1183/13993003.00217-2017 Year: 2017 CIPHER: a prospective, multicentre study for the identification of biomarker signatures for early detection of pulmonary hypertension Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension Year: 2020 Changes in pulmonary function and patient-reported outcomes during COVID-19 recovery: a longitudinal, prospective cohort study Source: ERJ Open Res, 7 (3) 00243-2021; 10.1183/23120541.00243-2021 Year: 2021 Use of bosentan for the treatment of pulmonary arterial hypertension in Spain: a multicenter, retrospective, observational study Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 A multicentre observational study of the prevalence, management and outcomes of subsegmental pulmonary embolism Source: Virtual Congress 2020 – Epidemiology, diagnosis and management of pulmonary embolism Year: 2020 PULSAR open-label extension: interim results from a phase 2 study of the efficacy and safety of sotatercept when added to standard of care for the treatment of pulmonary arterial hypertension (PAH) Source: Virtual Congress 2021 – All about pulmonary arterial hypertension Year: 2021 The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study Source: Eur Respir J, 53 (3) 1801587; 10.1183/13993003.01587-2018 Year: 2019 Standardised exercise training is feasible, safe and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension - results from a large European multicentre randomised controlled trial Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020 Baseline profile of patients initiating sitaxentan for pulmonary arterial hypertension (PAH): preliminary results from thelin outcomes for patients surveillance (TOPS) Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 The effect of smoking on the treatment outcome in patients with pulmonary tuberculosis: A prospective cohort study Source: Annual Congress 2011 - Clinical tuberculosis Year: 2011 Early treatment of borderline pulmonary arterial hypertension associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group, proof-of-concept study Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018 Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value Source: Eur Respir J 2007; 29: 432-434 Year: 2007 Noninvasive diagnostic strategy in pulmonary embolism: a prospective study in 1,136 out and inpatients Source: Eur Respir J 2001; 18: Suppl. 33, 381s Year: 2001 Interpreting risk reduction in clinical trials for pulmonary arterial hypertension Source: Eur Respir Rev, 27 (148) 180020; 10.1183/16000617.0020-2018 Year: 2018 Predictive value of fibrinogen/D-dimer ratio in patients with pulmonary embolism: a retrospective study Source: Annual Congress 2008 - Acute and chronic pulmonary thromboembolic disease Year: 2008 Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes Source: ERJ Open Res, 5 (4) 00094-2019; 10.1183/23120541.00094-2019 Year: 2019 Quantitative analysis of lung sounds for monitoring idiopathic pulmonary fibrosis: a prospective pilot study Source: Eur Respir J, 53 (3) 1802093; 10.1183/13993003.02093-2018 Year: 2019 A feasibility, randomised controlled trial of a complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): study protocol Source: ERJ Open Res, 5 (4) 00186-2019; 10.1183/23120541.00186-2019 Year: 2019